Monte Rosa Therapeutics (GLUE) Non Operating Income (2020 - 2026)

Monte Rosa Therapeutics' Non Operating Income history runs 7 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 52.08% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $16.4 million (up 41.46% YoY), while the FY2025 annual figure was $14.5 million, up 31.9% from the prior year.
• Non Operating Income was $5.6 million for Q1 2026 at Monte Rosa Therapeutics, up from $3.6 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $5.6 million in Q1 2026 to a low of $370000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $2.5 million across 5 years, with a median of $2.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income jumped 3320.75% in 2022, then retreated 6.91% in 2023.
• A 5-year view of Non Operating Income shows it stood at $1.7 million in 2022, then decreased by 6.91% to $1.6 million in 2023, then jumped by 63.44% to $2.6 million in 2024, then surged by 40.12% to $3.6 million in 2025, then surged by 53.42% to $5.6 million in 2026.
• The last three Non Operating Income figures came in at $5.6 million (Q1 2026), $3.6 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.